Tesamorelin Compound
Primary sources

Tesamorelin: Full Citation List

Every source cited across this site — primary clinical trials, pharmacokinetic analyses, meta-analyses, and regulatory records for Tesamorelin.

The following references are cited across this site. All Tesamorelin citations link to PubMed or the primary source; DOIs are provided where available.

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. DOI: 10.1056/NEJMoa072375 · PubMed 18057338
  2. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28. DOI: 10.1097/QAD.0b013e32830a5058 · PubMed 18690162
  3. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. DOI: 10.1097/QAI.0b013e3181cbdaff · PubMed 20101189
  4. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. DOI: 10.1093/cid/cis251 · PubMed 22495074
  5. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014;312(4):380-389. DOI: 10.1001/jama.2014.8334 · PubMed 25038357
  6. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. DOI: 10.1016/S2352-3018(19)30338-8 · PubMed 31611038
  7. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. DOI: 10.1001/archneurol.2012.1970 · PubMed 22869065
  8. Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, Heaton RK, Lee D, Sattler F. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. DOI: 10.1093/infdis/jiaf012 · PubMed 39813152
  9. González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-94. DOI: 10.1007/s40262-014-0202-x · PubMed 25358450
  10. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. J Clin Endocrinol Metab. 2011;96(1):150-158. DOI: 10.1210/jc.2010-1587 · PubMed 20943777
  11. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6). DOI: 10.1371/journal.pone.0179538 · PubMed 28617838
  12. Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16). DOI: 10.1172/jci.insight.140134 · PubMed 32701508
  13. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat: Relationship with Visceral Adipose Reduction. AIDS. 2011;25(10):1281-1288. DOI: 10.1097/QAD.0b013e328347f3f1 · PubMed 21516030
  14. Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. DOI: 10.1097/QAD.0000000000002897 · PubMed 33756511
  15. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10). DOI: 10.1371/journal.pone.0140358 · PubMed 26457580
  16. Rousakis A, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12.. 2026. DOI: 10.1016/j.orcp.2026.01.002 · PubMed 41545261
  17. Fourman LT, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024. DOI: 10.1097/QAD.0000000000003965 · PMC11365754
  18. Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2022;7(1):e40. DOI: 10.1017/cts.2022.515 · PubMed 36845310
  19. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH/LiverTox). 2020. NBK548730
  20. Fourman LT, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16). DOI: 10.1097/QAD.0000000000001614 · PubMed 28832410